Sign In
Buy UNCY
$5.01
-0.290 (-5.47%)
At Close: Jul 31, 2026
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
07:05am, Tuesday, 25'th Nov 2025
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “
NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel and Squire, P. C. , a nationally recognized shareholder rights law firm, is investigating certain officers and directors Quantum Corporation (N
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
07:05am, Wednesday, 12'th Nov 2025
- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which dem
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
07:05am, Monday, 03'rd Nov 2025
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “
Defendants allegedly overstated Unicycive's FDA readiness for its OLC NDA; later cGMP issues at a subcontractor led to FDA setbacks and stock drops.
Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill volume (7x) and pill count (2x) from
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
07:05am, Tuesday, 28'th Oct 2025
Cash runway into 2027, which is expected to support application resubmission, potential FDA approval, and launch of OLC Cash runway into 2027, which is expected to support application resubmission, po
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (N
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
02:55am, Tuesday, 14'th Oct 2025
NEW YORK , Oct. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March 29, 2024
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY
05:31pm, Monday, 13'th Oct 2025
LOS ANGELES , Oct. 13, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for vi
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:48pm, Monday, 13'th Oct 2025
LOS ANGELES , Oct. 13, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("U
NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY).
Portnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. Investors
03:41pm, Monday, 13'th Oct 2025
LOS ANGELES, Oct. 13, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of in
Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
02:34pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and certa
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
12:23pm, Monday, 13'th Oct 2025
NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive”
